The results suggest a potential unique regulatory mechanism for Erb-B2 in EC, hypothesizing that Erb-B2 may delay disease progression and improve prognosis by activating certain tumor-suppressive signaling pathways or inhibiting the expression of proteins involved in tumor cell invasion and metastasis (Ye et al., 1996). Here, ERBB2 is linked to neoplasm.